Usa Stocks Insider
  • Business
  • World
  • Investing
  • Stocks

Usa Stocks Insider

  • Business
  • World
  • Investing
  • Stocks
Investing

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

by admin June 12, 2025
June 12, 2025
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

Radiopharm Theranostics (ASX:RAD, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for RAD101 to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease.

RAD101 is the Company’s novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors, including cerebral metastases.

‘The FDA’s Fast Track Designation for RAD101 highlights the seriousness of recurrent brain metastases as a condition and the unmet medical need for innovative products that can differentiate between tumor recurrence and radiation necrosis or pseudprogression,’ said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. ‘RAD101 represents a promising advancement in improving diagnostic precision for brain metastases, offering hope for more effective clinical decision-making in the over 300,000 patients diagnosed annually in the U.S. We are excited to advance our Phase 2 clinical trial and anticipate sharing topline results in the second half of 2025.’

The FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address an unmet medical need. A Sponsor that receives Fast Track designation may be eligible for more frequent meetings and communications with the FDA and rolling review of any application for marketing approval. A Sponsor’s drug receiving Fast Track designation also may be eligible for Priority Review if relevant criteria are met.

About the Phase 2 Clinical Trial of RAD101

The U.S. multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic performance of 18F-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins. The primary objective of the study is concordance between 18F-RAD101 positive lesions and those seen in conventional imaging (MRI with gadolinium) in participants with suspected recurrent brain metastases. Secondary endpoints are accuracy, sensitivity and specificity of RAD101 in identifying tumor recurrence versus radiation necrosis in previously stereotactic radiosurgery (SRS)-treated brain metastases.

About RAD101

RAD101 is the Company’s novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors, including cerebral metastasis. Targeting FASN activity may allow for the more accurate detection of cancer cells, representing a clinically relevant method for the imaging of brain metastases. Positive data from the Imperial College of London’s Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases (both SRS pre-treated and treatment naïve patients) showed significant tumor uptake that was independent from the tumor of origin. The study further indicated that PET-MRI may potentially represent a non-invasive prediction of overall-survival, warranting larger studies.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com .

Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (Formerly Stern IR)
E: annemarie.fields@precisionaq.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Noble Mineral highlights Mann West Nickel Sulphide Initial Resource as announced by Canada Nickel
next post
10‑Year Yield Warning! ADX + RSI Point to a Major Shift

You may also like

Walker Lane Resources Announces Terms for Private Placement...

June 10, 2025

Hempalta Provides Strategic Update Regarding Equipment Sale and...

June 7, 2025

Juggernaut Exploration

June 14, 2025

Randy Smallwood: Silver Set for Bull Run, Gold...

June 26, 2025

John Ciampaglia: Uranium Turnaround? Spot Price Pop, Stocks...

June 27, 2025

Crypto Market Recap: Strategy Eyes US$1 Billion Capital...

June 7, 2025

Maiden Underground Ore Reserves Underpins FY26 Production

June 26, 2025

RUA GOLD Announces Filing of Prospectus Supplement

June 19, 2025

Silver Price Surges to US$37, Highest Value Since...

June 18, 2025

Gold Price, Markets Trade Flat After US Strikes...

June 24, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Russian minister dies by suicide hours after getting fired by Putin, officials say

      July 8, 2025
    • ‘We have to keep growing:’ Mother of killed Israeli hostage in battle to have a grandchild with his harvested sperm

      July 8, 2025
    • King Charles to emphasize bonds between UK and France as he welcomes Macron in first European state visit since Brexit

      July 8, 2025
    • The Best Five Sectors, #26

      July 8, 2025
    • Questcorp Mining Continues Exploration in Advance of Drilling at the La Union Gold & Silver Project in Mexico

      July 8, 2025

    Categories

    • Business (64)
    • Investing (256)
    • Stocks (118)
    • World (264)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: usastocksinsider.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 usastocksinsider.com | All Rights Reserved